Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Publication Type:

Journal Article

Source:

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 26, Issue 14, p.2390-3295 (2008)

Keywords:

2008, Acute Disease, Adolescent, Adult, Aminoglycosides, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Asparaginase, Child, Child, Preschool, Clinical Research Division, Cytarabine, Disease-Free Survival, Dose-Response Relationship, Drug, Female, Humans, Infant, Leukemia, Myeloid, Male, MITOXANTRONE, Survival Rate

Abstract:

While gemtuzumab ozogamicin (GTMZ) is commonly used in the treatment of acute myeloid leukemia (AML) in combination with standard chemotherapy agents, the pediatric maximum-tolerated dose (MTD) of GMTZ in combination with chemotherapy has not been determined.